# Specificity and sensitivity panels for SARS-CoV-2 detection; 06-08-2020

## Store the panels at -20°C or below until testing

#### Contents

Blinded specificity panel: 10 simulated clinical specimens (1ml) containing either human respiratory seasonal viruses, heat-inactivated SARS-CoV-2 virus or no virus (a negative control) in MEM with Hanks' salts and Hep2 cells (10.000 cells/ml). Treat these specimens as you would do with clinical specimens. All specimens require nucleic acid extraction before running them in an RT-qPCR, or the specific treatment as required by the used work flow.

Blinded sensitivity panel: 7 simulated clinical specimens (1ml) containing different loads of heat-inactivated SARS-CoV-2 virus in MEM with Hanks' salts and Hep2 cells (10.000 cells/ml). Treat these specimens as you would do with clinical specimens. All samples require nucleic acid extraction before running them in an RT-qPCR, or the specific treatment as required by the used work flow.

#### Request to the laboratories

For the detection of SARS-CoV-2 in the specificity- and sensitivity panel, please use the work flow that is, or will be, used for testing of patient clinical specimens.

#### Reporting of the results

Please report your findings as soon as possible after receiving the panels.

We kindly request you to report the results of the panels, including information about the used work flow (equipment and reagents/kits and other conditions) to us (5.1.21 grivm.nl) for evaluation.

To this end you have received by email a reporting form. You will receive the decoding of the panel confidentially after we have received and evaluated your results. A report with the results of all participating laboratories will follow after all data has been processed. Is possible that the results will be used to write a paper about our findings.

### Questions

